Novartis AG's hopes of Adakveo becoming a blockbuster have taken a hit with the news that the already-approved sickle cell disease therapy has failed a late-stage trial and is being reviewed by the European Medicines Agency.
Pfizer In Pole Position To Benefit From Novartis Sickle Cell Drug Setback
Adakveo Fails A Phase III Study
Pfizer joined Novartis as the market leader in sickle cell disease when it acquired Global Blood Therapeutics last year. The US giant's Oxbryta may now move ahead following a clinical and regulatory setback for the Swiss major's Adakveo.
More from Blood and Clotting
More from Therapy Areas
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
• By
After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.